ABSTRACT
disorders in approximately 25% of autistic individuals (6) . Twin studies (7, 8) have indicated that genetic factors play a prominent role in the etiology of ASD although the genetics of autism appears to be extremely complex. There has been enormous progress in establishing the genetic architecture of ASD and there are at least 100 genes known to confer risk of ASD (9, 10) . There is also increasingly strong evidence that environmental factors, alone or in conjunction with genotype, can contribute to the risk for ASD (11) . These findings have led to a widespread consensus that there are different biological forms of ASD that may necessitate different diagnostic, preventative and treatment strategies.
ASD is currently diagnosed based on behavioral characteristics exhibited by an affected child (12) . While specialist clinicians are able to confidently diagnose children as young as 24 months (13), the average age of diagnosis in the United States is over 4 years (2, 14) . Families often experience long waits to receive a definitive diagnosis due to the paucity of trained clinicians able to perform diagnostic assessment. Early diagnosis is important because intensive behavioral therapies are not only effective in reducing disability in many children with autism (15) (16) (17) , but, the benefit of early intervention is greater the earlier the intervention is started.
Unfortunately, there is currently no reliable biomarker that can be used to identify children at risk for ASD (18) . Because of the genetic complexity of ASD, there is currently no M A N U S C R I P T
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5 clinically meaningful genotyping carried out to detect ASD. There have been recent intriguing neuroimaging studies indicating that alterations of brain function or structure as early as 6 months may be valuable indicators of a higher risk for autism (19, 20) . However, it is unlikely that comprehensive structural and functional magnetic resonance imaging is a practical approach to detecting ASD in young children. Other, more cost effective and widely applicable biomarker strategies must be discovered.
We previously demonstrated that a metabolomics approach for the detection of autism risk holds substantial promise (21) . In our preliminary study, we identified a subset of 179
features that classified ASD and TYP children with 81% accuracy. Metabolism-based analysis has the merit of being sensitive to interactions between the genome, gut microbiome, diet, and environmental factors that contribute to the unique metabolic signature of an individual (22) .
Metabolic testing can provide important biomarkers toward identifying the perturbations of biological processes underlying an individual's ASD. Past studies have been underpowered to identify metabolic perturbations that lead to actionable metabolic subtypes (23) .
To test for metabolic imbalances that can reveal subtypes of ASD subjects, we conducted the Children's Autism Metabolome Project (CAMP, ClinicalTrials.gov Identifier NCT02548442). CAMP recruited 1,100 young children (18 to 48 months) with ASD, intellectual disability or typical development. Research reliable clinicians confirmed the child's diagnosis and blood samples were collected under protocols designed specifically for metabolomics analyses. The CAMP study is the largest metabolomics study of ASD to date.
The current study was motivated by observations of AA dysregulation in West et al. (21) and in preliminary analysis of the CAMP samples. The relevance of AA dysregulation to ASD is reinforced by Novarino (24) Tarlungeanu (25) demonstrated that altered transport of BCAAs across the blood brain barrier led to dysregulation of AA levels and neurological impairments. We sought to determine whether dysregulation of AAs was a more pervasive phenomenon in individuals with ASD.
Thus, we set out to identify metabotypes indicating the dysregulation of AAs in individuals with ASD and to determine whether these metabotypes might be diagnostic of subsets of individuals.
A metabotype is a subpopulation defined by a common metabolic signature that can be differentiated from other members of the study population (26) . Metabotypes of ASD can be useful in stratifying the broad autism spectrum into more biochemically homogeneous and clinically significant subtypes. Stratification of ASD based on distinct metabolism can inform pharmacological and dietary interventions that prevent or ameliorate clinical symptoms within a metabotype.
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METHODS AND MATERIALS
CAMP Participants
The CAMP study recruited children, ages 18 to 48 months, from 8 centers across the United States (Supplemental Table S1 ). were not included in the current study. Children entering the study as TYP were not routinely administered the ADOS-2. The Social Communications Questionnaire (SCQ) was administered for a subset of 65 TYP children as a screen for ASD. Of these, 9 were referred for subsequent
Four received a diagnosis of ASD (and were included in this study) and 5 received a diagnosis of TYP.
Training and Test Sets
A training set was used to identify metabotypes associated with ASD and a test set was used to evaluate the reproducibility of the metabotypes. The sample size of the training set was designed to detect metabotypes with a sensitivity (metabotype prevalence) > 3% and specificity > 85% with a power of 0.90 (Supplemental Table S2 ). The training set (N=338, ASD=253, TYP=85) was established and analyzed, then as recruitment continued, the test set (N=342, ASD=263, TYP=79) was established when sufficient subjects were available to match the training set demographics (Supplemental Table S3 ).
Phlebotomy Procedures
Blood was collected from subjects after at least a 12 hour fast by venipuncture into 6ml sodium heparin tubes on wet ice. A minimum of a 2 ml blood draw was required for sample inclusion in the computational analyses. The plasma was obtained by centrifugation (1200 X G for 10 minutes) and frozen to -70 o C within 1 hour.
Triple Quadrupole LC-MS/MS Method for Quantitative Analysis of Biological Amines
The 
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Bioinformatic Analysis
The concentration values of each metabolite were log base 2 transformed and Z-score normalized prior to analyses. Analysis of covariance (ANCOVA) and pairwise Pearson correlation analysis were performed on each amine compound. False discovery rates were controlled for multiple testing using the Benjamini and Hochberg (27) (29) . Welch T-tests were used to test for differences in study populations. The independence of subject metadata relative to the metabotypes was tested using the Fisher Exact test statistic with an alpha of 0.05 to reject the null hypothesis. These analyses were conducted with R (version 3.4.3).
Establishing and Assessing Diagnostic Thresholds
A heuristic algorithm was developed to identify individual biomarkers able to discriminate ASD subpopulations, indicative of a metabotype, using a threshold (Supplemental Figure S1) for metabolite abundance or ratios. Diagnostic thresholds were established in the training set to generate a subpopulation with at least 10% of the ASD population while minimizing the number of TYP subjects in the subpopulation. A subject exceeding the diagnostic threshold was scored as a metabotype-positive ASD subject and the remaining subjects as metabotype-negative.
Diagnostic performance metrics of specificity (detection of TYP), sensitivity (detection of ASD) M A N U S C R I P T
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and positive predictive value (PPV, percent of metabotype-positives that are ASD) were calculated based on metabotype status (positive or negative) and ADOS-2 diagnosis (ASD or TYP).
Permutation analysis was performed to test the probability that the observed diagnostic performance values from threshold setting and subpopulation prediction could be due to chance. Chance was assessed using 1000 permutations of subject diagnoses in the training set for threshold setting and subpopulation prediction or test set following subpopulation prediction.
In both permutation procedures, the probability that observed biomarker performance metrics were due to chance was calculated based on the frequency that the observed sensitivity, specificity, and PPV were met or exceeded in the random permutation set.
When the diagnostic ratios were combined into panels of ratios to test for ASD associated metabotypes, the minimum performance required to consider a metabotype as reproducible were a sensitivity ≥ 5%, a specificity ≥ 95%, and a PPV ≥ 90% in both training and test sets.
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RESULTS
Children's Autism Metabolome Project (CAMP) Study Demographics
The training and test sets of subjects were chosen with appropriate power and randomization (Supplemental Table S3 ). The ASD prevalence, DQ, and gender composition between the training and test sets are equivalent (p value > 0.05). However, the ASD population contains 16.5 % more males than the TYP population (p value < 0.01). The ASD population is slightly older than the TYP by 3.3 months (p value < 0.01) and the ASD subjects within the training set are 1.4 months older than ASD subjects in the test set (p value < 0.01).
Analysis of Amine-Containing Metabolites between ASD and TYP Study Populations
Analysis of covariance (ANCOVA) was performed on 31 amine containing metabolites in the training set of subjects to test the effect of gender or diagnoses controlling for subject age on metabolite means. No significant differences were identified in metabolite abundance values for diagnosis, age, sex, gender or their interactions (Supplemental Table S6 ). These results suggest that within the demographic ranges in this study, the differences in subject age or sex have little impact on metabolite abundance. Therefore, the differences in the composition of ASD and TYP study populations are unlikely to have significant impact on study results.
Metabolite Correlations within ASD Reveal Distinct Clusters of Amine Metabolites
We then examined the relationship among the amine metabolites in the training set of . We decided to focus our analysis on the glycine cluster metabolites that are negatively correlated with BCAA metabolites. Proline was removed from further analysis because it was not negatively correlated with the BCAAs.
Phenylalanine was removed because it is not a BCAA metabolite.
Identification of Amino Acid:BCAA Imbalance Metabotypes Associated with ASD
The negative correlation between the BCAA and glycine cluster led us to evaluate ratios of these AA as predictors of ASD diagnosis. Ratios can uncover biological properties not evident with individual metabolites and increase the signal when two metabolites with a negative correlation are evaluated. This strategy, for example, formed the basis of the standard phenylketonuria (PKU) diagnostic using a ratio of phenylalanine and tyrosine (30) . Based on analysis of boxplots (Supplemental Figure S2) , we created ratios with one of the BCAAs in the denominator and one of the glycine cluster metabolites in the numerator. Thresholds for the ratios were set in the training set and evaluated in the test set of subjects ( Table 1) . The BCAA ratios of glutamine, glycine, ornithine and serine identified subpopulations of subjects associated with an ASD diagnosis at a rate higher than chance in both training and test sets (Supplemental Tables S7 and S8 ). Table S9 ). However, requiring that the subject be positive for all three Glycine:BCAA ratios, results in a specificity of 98.8% and PPV of 96.0%. Through this process, we identified groups of subjects that exhibited an Amino Acid Dysregulation Metabotype (AADM). Subjects were identified by AADM when they exceeded an established threshold for all three AA:BCAA ratios. Since the nomenclature for these biomarkers can quickly become confusing, we have designated different AADMs using the numerator metabolite e.g. AADM glutamine (Figure 2) . Not all ratios of AAs to BCAA resulted in diagnostic differences between the ASD and TYP groups ( Table 2 
AADMs Define a Diagnostic for BCAA Dysregulation Associated with ASD
The ASD subjects identified by each AADM were evaluated to assess the extent of overlap. We found that there is substantial overlap of the subjects identified by each of the metabotypes (Figure 3) . However, each of the metabotypes also identifies a unique group of subjects. The AADM glutamine identified 7.9% of the ASD subjects in the total CAMP population, AADM glycine 9.7%, and the AADM ornithine 9.1%, with PPVs of 97.6%, 94.3% and 92.2%
respectively. Combining all three AADM subtypes together (AADM total ), identified 16.7% of ASD subjects in the CAMP population with a specificity of 96.3% and a PPV of 93.5% (Figure 3 A) .
Principal component analysis (PCA) of the metabolite ratios utilized in AADM glycine , AADM glutamine , and AADM ornithine was performed to test if an unsupervised method could identify subjects with AA dysregulation. A majority (80%, 74/92) of the AADM-positive subjects were separated from the unaffected subjects (Figure 3 B) . Since the composition of subject sex and age differed between the ASD and TYP populations, the impact of these variables was evaluated in the AADM positive and negative populations. Differential analysis of reproducible AADM positive and negative subjects' metabolite levels with respect to age or sex did not identify statistically significant changes in abundance (Supplemental Results, Supplemental Tables S11 and S12). Females with ASD were 2.1 fold (odds ratio 2.8, p value 0.002) more likely to be identified by AADM ornithine and AADM glutamine than would be expected by chance (Supplemental Table S13 ). The AADM glycine did not demonstrate a predictive sex bias. again this was associated with ASD-like symptoms. Interestingly, neither study reported elevated plasma levels of glycine, ornithine, or glutamine. The imbalance of amino acid levels in CAMP strongly suggests that other perturbations in BCAA metabolism may be a risk factor for the development of ASD. Importantly, the metabolomic results reported here provide a mechanism for stratifying the larger group of children with ASD into an AADM positive subgroup to enable a more targeted approach to understanding the etiology of this form of ASD. For example, the AADMs we identified may reveal a disruption of the mTORC1 system which could be an underlying reason for lower free plasma BCAA levels. Cellular levels of BCAA as well as other amino acids are maintained through signaling associated mTORC1 and the transcription factor ATF4 (33) . Dysregulation of the mTOR pathway is an underlying cause of amino acid dysregulation that is associated with ASD and tuberous sclerosis (34) .
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The AADMs provide one pathway to much earlier diagnosis of a substantial subset of children with ASD. Earlier diagnosis may also provide the opportunity for earlier biological intervention. BCAA supplementation or high protein diet has been used in mouse models (24) and human patients (31) with BCKDK deficiency to successfully reduce ASD symptoms and improve cognitive function. Defining a group of AADM positive children may enable stratification of the autistic population as a precursor to targeted intervention through dietary supplementation or specialized diet. Currently, clinical trials of common therapies such as vitamin and mineral supplements, carnitine and gluten-free casein-free diets, apply these therapies to all participants. Metabotyping subjects prior to treatment and monitoring metabolite levels provides the opportunity to assess patient compliance and response, and to make adjustments to treatment based on objective measurement of the metabolic profile of the individual subject. It is likely that this strategy would substantially improve positive treatment outcomes.
This study does have some limitations. The levels of blood plasma amine metabolites are not directly relatable to brain levels (35) making direct association of changes in plasma levels to changes in brain levels difficult. The CAMP study focused on recruitment of a large sample of children with ASD and age-matched typically developing controls. Logistical and financial constraints precluded our ability to recruit a large enough sample of children with developmental delays without ASD. Thus, the specificity of ADDM for ASD relative to other neurodevelopmental disorders is currently unclear. This is an important issue that will need to be resolved in future studies. In addition, longitudinal samples are not available to analyze whether AADMs are stable over time. Finally, this study lacks animal models or tissue samples that could be used to dissect enzymatic and expression analysis to identify the molecular mechanisms underlying AADM. While we cannot explain the alterations in metabolism, we have demonstrated that our approach provides stratification of subjects for which future studies and perhaps targeted treatments could be carried out.
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This study demonstrates one approach to analyzing the metabolism of ASD to successfully identify reproducible metabotypes. Analysis of the CAMP study samples is ongoing and there will be additional metabotypes which will be diagnostic for subsets of children with ASD. Stratifying ASD based on metabotypes offers an opportunity to identify efficacious interventions within metabotypes that can lead to more precise and individualized treatment.
The hope is that by combining the established metabotypes into a more comprehensive diagnostic system, that a substantial percentage of children at risk for ASD will be identifiable at a very early age. The observed diagnostic performance occurred in less than 5% of 1000 permutations of subject diagnosis in both training and test sets. Stable isotope labeled (SIL) internal standards (Supplemental Table S5 ) were used to normalize the signal for each analyte to account for variations in the matrix and sample preparation. For analytes in which no SIL internal standard was available, a surrogate SIL internal standard was chosen based on the work of Gray et al.
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TABLES
(1) using a structurally similar analyte (Supplemental Table S4 ).
Chromatographic separation was performed using reverse-phase chromatography on a HSS T3 2.1 x 150mm, 1.8µm column (Waters). Column temperature was maintained at 45ºC.
The mobile phase was composed of 0.1% formic acid in water and 0.1% formic acid in acetonitrile.
A gradient elution was performed which separates the analytes over the course of 7.5 minutes per injection using a flow rate of 0.6 ml/min. Table   S10 ). Since there are slight differences between the age of TYP and ASD subjects (3.3 months) and between the age of ASD subjects in the training and test set (1.4 months), we tested if the age of the subject within AADM positive population was associated with the ratio of metabolite abundance levels. No differences in mean (FDR > 0.05) or correlations (FDR > 0.05) of abundance levels of metabolite ratios or individual metabolites of AADM positive populations were found in association with the age of the subjects (Supplemental Table S11 ). Figure S1 . Outline of computational procedures utilized to set diagnostic thresholds and to evaluate diagnostic performance. Diagnostic thresholds were set for each metabolite or metabolite ratio in the training set and the threshold was applied to the training or test set to identify the affected subpopulation and determine the observed diagnostic performance. Permutation analysis was performed to evaluate the frequency at which the observed diagnostic performance occurred by chance. A diagnostic test was considered to identify a relevant metabolic subpopulation if the observed performance metrics occurred in less than 5% of 1000 iterations of random permutations of the subjects' diagnoses. Blue boxes indicate groups that are comprised of greater than 90% ASD subjects (90% PPV). These groups include at least 5% of the training set of ASD subjects (5% sensitivity). Glycine, alanine, asparagine, aspartic acid, GABA, glutamic acid, homoserine, ethanolamine, sarcosine, serine and taurine exhibited elevated metabolite levels in ASD subjects, while leucine exhibited decreased metabolite levels in ASD subjects. Red = ASD, Black = TYP; TYP, Typically Developing; ASD, Autism Spectrum Disorder. BAIBA, β-Aminoisobutyric Acid; GABA, γ-Aminobutyric acid, bAla, β-alanine; Hci, Homocitrulline; Hse, Homoserine; ETA, Ethanolamine; Sar, Sarcosine; Tau, Taurine; Hyp, 4-Hydroxyproline; Cit, Citrulline. 
Metabolite Ratios and Metabolites
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